Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Summary

This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM326, and to observe the Pharmacokinetics, Pharmacodynamics and immumogenicity of CM326 in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).

Timeline

Start

2024-06-30

Primary completion

2026-06-30

Completion

2026-06-30

Drugs

Indications